| Gene symbol | CD40LG | Synonyms | CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq26.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD40 ligand | ||||
| Gene symbol | CD70 | Synonyms | CD27-L, CD27L, CD27LG, LPFS3, TNFSF7, TNLG8A | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.3 | dbXrefs | |
| Description | CD70 molecule | ||||
| Gene symbol | TLR4 | Synonyms | ARMD10, CD284, TLR-4, TOLL | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | toll like receptor 4 | ||||
| GTO ID | GTC1944 |
| Trial ID | NCT03619278 |
| Disease | HIV Infection |
| Altered gene | CD40LG|TLR4|CD70 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | HIVACAR |
| Co-treatment | 10-1074 antibody|romidepsin |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | A Phase I/IIa, Randomised Study to Evaluate the Safety and the Effectiveness of a Combination of Therapeutic Vaccine, Broadly Neutralising Antibody (10-1074), and the Latency Reversing Agent Romidepsin to Achieve a Remission of HIV Infection in Chronically HIV-infected Participants Under Stable Combined Antiretroviral Therapy |
| Year | 2020 |
| Country | China |
| Company sponsor | David Garcia Cinca |
| Other ID(s) | 2017-000566-30 |
| Cohort1: HIVACAR | |||||||||
|
|||||||||
| Cohort2: placebo | |||||||||
|
|||||||||